New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 14, 2014
07:09 EDTRTRXRetrophin raises FY14 revenue view to $19M-$21M from $10M-$12M
One estimate $11M. Raises FY15 revenue view to $35M-$40M from $19M-$21M, one estimate $20M. Retrophin CEO Martin Shkreli said, “Reimbursement of Chenodal has remained robust, and initial efforts to find undiagnosed cerebrotendinous xanthomatosis patients are promising. We have raised our guidance for 2014 and 2015 revenue accordingly. We are very comfortable with our current cash balance and future obligations. The success of Chenodal significantly reduces our cash needs and may propel the company to profitability in the near-term. As such, we have no need or desire to explore a dilutive equity offering unless it is accompanied by an accretive and strategic acquisition. Retrophin remains opportunistic with respect to M&A and has strong access to both debt and equity capital.”
News For RTRX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 14, 2014
08:01 EDTRTRXRetrophin divests non-core assets to Turing Pharmaceuticals
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use